Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
LLY Stock Chart & Stats
$906.86
$17.01(2.20%)
At close: 4:00 PM EST
$906.86
$17.01(2.20%)
Day’s Range― - ―
52-Week Range$623.78 - $935.63
Previous CloseN/A
Volume1.27M
Average Volume (3M)3.48M
Market Cap
$857.33B
Enterprise Value$718.43B
Total Cash (Recent Filing)$9.91B
Total Debt (Recent Filing)$42.51B
Price to Earnings (P/E)44.9
Beta0.69
Next Earnings
Feb 11, 2026EPS Estimate
7.03Last Dividend Ex-Date
Aug 15, 2025Dividend Yield0.7%
Share Statistics
EPS (TTM)7.02
Shares Outstanding945,383,700
10 Day Avg. Volume3,135,883
30 Day Avg. Volume3,481,232
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)48.99
Price to Sales (P/S)15.44
P/FCF Ratio1.68K
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue12.09
Enterprise Value/Gross Profit14.56
Enterprise Value/Ebitda28.60
Forecast
1Y Price Target
$917.63Price Target Upside1.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth ProspectsThe company's pipeline strategy is beginning to bear fruit, with recent approval of donanemab supporting growth prospects.
Market ShareLilly's incretin leadership is strengthening, with TRx share expanding to approximately 58%, driven by sustained demand.
Product PerformanceTirzepatide continues to show impressive results, reinforcing Lilly's dominance in the metabolic disease market.
Bears Say
Investment RisksThere are many complex factors and risks involved in Eli Lilly's story, making it a challenging investment for those not accustomed to binary event risks.
Pricing ConcernsLLY shares sold off following the administration’s third press conference on drug pricing/tariffs, which included commentary from President Trump on obesity pricing suggesting GLP-1 therapies could be negotiated down to $150/month, which is lower than investors have been expecting.
Regulatory ChallengesOrforglipron was not included in the FDA’s new expedited priority review vouchers announcement.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $623.78 and its highest was $935.63 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $857.33B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Feb 11, 2026 which is in 97 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2025. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $5.692 by $1.328.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.5 which represents an annual dividend yield of 0.7%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 7.03.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 945,383,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $7.02 in its last earnings report, beating expectations of $5.692. Following the earnings report the stock price went up 3.807%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Currently, no hedge funds are holding shares in LLY
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$917.63 (1.19% Upside)
$917.63 (1.19% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 4.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.31%
12-Months-Change
Fundamentals
Return on Equity
96.82%
Trailing 12-Months
Asset Growth
52.02%
Trailing 12-Months
Company Description
Eli Lilly & Co
Eli Lilly and Company (LLY) is a global healthcare leader based in Indianapolis, Indiana, that focuses on the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in several sectors, including diabetes care, oncology, immunology, neuroscience, and pain management. Eli Lilly's core products include insulin therapies, cancer treatments, and medications for various chronic and acute conditions, including depression and autoimmune disorders.
LLY Company Deck
LLY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter with significant revenue growth, increased market share, and notable FDA and EU approvals. However, the company faced challenges with price declines in the U.S. and increased expenses. Despite these challenges, the overall sentiment is positive due to the strong financial performance and strategic advancements.View all LLY earnings summariesLLY Revenue Breakdown
90.47% Net product revenue
9.53% Collaboration and other revenue
LLY Stock 12 Month Forecast
Average Price Target
$917.63
▲(1.19% Upside)
Technical Analysis
Ownership Overview
10.14% Insiders
23.18% Mutual Funds
0.26% Other Institutional Investors
48.43% Public Companies and Individual Investors